Three improvements are needed for ICH to push local pharmaceutical enterprises into international competition

[China Pharmaceutical network industry trends] the accession of CFDA to ICH is undoubtedly a new situation for Chinese local pharmaceutical enterprises The article of the State Food and Drug Administration mentioned that joining ICH "will promote the international innovative drugs to enter the Chinese market as soon as possible, meet the clinical drug demand, and improve the innovation ability and international competitiveness of the domestic pharmaceutical industry." (ICH's efforts to push local pharmaceutical companies into international competition still need three major improvements) "China's new drugs are ushering in a new golden decade of development." On September 23, Chen Kaixian, academician of the Chinese Academy of Sciences, said generously at the 9th China Pharmaceutical entrepreneur scientist investor conference Behind this, the State Food and Drug Administration (CFDA) disclosed as early as June 2017, and the International Conference for the technical coordination of human drug registration (ICH) officially approved CFDA as the eighth regulatory agency in the world This means that the road for Chinese drugs to enter the international market is less bumpy Of course, this also means that the competition between Chinese local pharmaceutical companies and multinational pharmaceutical companies may face a positive confrontation Zuo min, President of Shanghai Pharmaceutical Group, said: "if we compare our local enterprises to football (teams), we (originally) fought in the secondary market in Asia, but) threw it to the final of the world cup." Among the participants, China's pharmaceutical innovation environment has gradually become one of the consensus At the same time, you guys also discussed how to improve the innovation ability and international competitiveness of domestic pharmaceutical enterprises, and put forward three promotion paths of global innovation, integration and supporting measures There is still a huge gap between R & D and pharmaceutical industry In recent years, the pharmaceutical industry has been highly praised by capital, and the prospect of pharmaceutical industry as a sunrise industry has also been confirmed by figures Chen Kaixian introduced at the meeting that the scale of China's pharmaceutical market has ranked the second in the world If we take the level of the United States as the benchmark value of 100, the relative scale of China in 2008 is 142013, 292017, 45, which can be seen from the scale growth of China's pharmaceutical industry Later, Chen Kaixian put forward an ambitious goal: "our goal is to move from imitation oriented to innovation oriented, from a pharmaceutical power to a pharmaceutical power." However, the difficulty of new drug research and development is obvious to all: it takes an average of 10-15 years to develop and market a new drug successfully, with a cost of US $2.6 billion In recent years, the cost of new drug research and development has increased due to the increasingly complex clinical trials, larger scale and higher early failure rate Moreover, there is a gap in R & D investment between China's local pharmaceutical enterprises and multinational pharmaceutical enterprises that cannot be ignored "Roche's last year was 10 billion US dollars, and our Shanghai Pharmaceutical last year was about 800 million (currency is not specified) Such an order of magnitude difference is how to face their competition in the era of product being the king and innovation being the king?" Zuo min proposed this in the round table dialogue Problem However, although it is difficult for Chinese pharmaceutical companies to match the global famous pharmaceutical companies in the total amount and average intensity of R & D investment, in terms of R & D investment intensity, there are also leading listed pharmaceutical companies in China that are close to some global enterprises According to the data listed by Chen Kaixian, taking 2015 as an example, the top 10 Chinese listed pharmaceutical companies with relatively strong capital invested 5.069 billion yuan in R & D, with an average R & D investment intensity of about 5.95%, while the R & D investment intensity of Hengrui Pharmaceutical Co., Ltd located in Hengrui Pharmaceutical Co., Ltd is 9.57%, comparable to the last company in the top 10 pharmaceutical companies in the world It is undoubtedly a new situation for Chinese local pharmaceutical enterprises to join the ICH through the three ways of improving international competitiveness The article of the State Food and Drug Administration mentioned that joining ICH "will promote the international innovative drugs to enter the Chinese market as soon as possible, meet the clinical drug demand, and improve the innovation ability and international competitiveness of the domestic pharmaceutical industry." China's local pharmaceutical enterprises will enter the international competition driven by China food and Drug Administration's accession to ICH Such a competition situation naturally requires improving innovation ability For the path of innovation in the future, Zhou Hong's view is that innovation should be globalized "Do Swiss small countries rely on Swiss scientists? No, it requires global scientists, global innovation and global market to make them as big as they are today?" In terms of innovation globalization, Hao Xiaofeng, President of Kanghong pharmaceutical, specifically mentioned supporting measures "Globalization was supposed to come naturally, but unfortunately the water didn't come to the canal." Hao Xiaofeng said that China's market size should theoretically account for 20% of the world's total, and the internal power of production and R & D should be sufficient, but the current situation is not so After joining the ICH in the future, China's "channel" was opened until the supporting policies were followed up and revised, and the globalization of pharmaceutical innovation was inevitable He Wei, member of the Standing Committee of the CPPCC National Committee, pointed out that there are structural problems in China's pharmaceutical industry, affecting the development of the pharmaceutical industry, and at the same time, it is not conducive to China's formation of large-scale pharmaceutical enterprises with international competitiveness By the end of 2015, there were 5065 pharmaceutical manufacturers in China, but less than 20% of the sales were over 100 million yuan, while the sales revenue of the top 100 enterprises accounted for only about 30% of the total, and the industrial concentration was low Therefore, he proposed that we should "support small and medium-sized enterprises with innovative ability and characteristic resources to be better and stronger through restructuring, listing, combination and other ways." Drive capacity consolidation " Original title: ICH brings Chinese medicine to face the global innovation and competition three major improvements are needed for pharmaceutical enterprises to meet the challenge reporter: Li shaoting teaches you to use app (Pharma) in the whole process to seize the opportunity of pharmaceutical machinery